You may be confused. LSD sounds like something that belongs at a concert in the 60s, not a clinic. That’s how a lot of patients feel when they hear of LSD as therapy for depression and MDD, and that confusion is real. But so is the fact that a pharmaceutical-grade form of LSD is now in a Phase 3 trial for major depressive disorder (MDD), and the FDA has taken notice.
So, if you’re living with depression that hasn’t responded to treatment, LSD therapy is worth understanding properly, without the hype and without the eye-roll. Here’s what it actually is, what the research has found so far, what nobody knows yet, and what’s realistically within reach today.
What Is LSD Therapy?
LSD (lysergic acid diethylamide) is a semi-synthetic compound derived from ergot, a fungus that grows on grains like rye. It was first synthesized in the late 1930s, studied in psychiatry for years, and then pushed out of research for decades after it was criminalized.
Like psilocybin, it’s classified as a classic psychedelic, meaning it acts on the brain’s serotonin system and produces hours of altered perception, emotion, and thought.
LSD therapy, as it’s being tested now, has very little in common with the LSD from the 60s concerts. The trials use a pharmaceutical-grade formulation, an orally disintegrating tablet that dissolves in the mouth, given as a single, precisely measured dose in a supervised clinical setting.
Staff monitor participants throughout the dosing day, and in the most recent depression trial, people needed about six hours on average to meet the end-of-session criteria for leaving, with everyone meeting them by hour eight.
How LSD May Help With Major Depressive Disorder
LSD binds to several serotonin receptors, most notably the 5-HT2A receptor, which is involved in mood, perception, and mental flexibility. One leading idea is that this action briefly loosens the rigid, repetitive thinking that depression tends to lock in, and opens a window where the brain is more adaptable and new patterns can form.
That’s a working theory, not a settled explanation. Researchers are still mapping how a few hours of altered consciousness can translate into weeks of relief, and no one should tell you the mechanism is fully understood because it’s not.
Where the Research Into LSD-Assisted Therapy Shows
The depression evidence is still pretty new, and most of it comes from one drug program, the one for DT120, a formulation of LSD developed by Definium Therapeutics (formerly MindMed).
Here’s where it stands:
- Emerge (Phase 3, MDD, 2026): 149 adults with major depressive disorder received either a single 100 µg dose or placebo. At the six-week mark, depression scores on the MADRS scale had dropped by 13.3 points in the LSD group versus 5.2 points in the placebo group, a difference of 8.1 points. The gap was already visible after one week (14.2 points) and was still present at week 12 (7.3 points).
- Ascend (Phase 3, MDD, ongoing): The second pivotal depression trial began dosing in May 2026 and plans to enroll roughly 165 people across three groups: 100 µg, 50 µg, and placebo. Results are expected in 2027.
- Voyage and Panorama (Phase 3, anxiety, 2026): Both trials in generalized anxiety disorder met their primary endpoints. They’re not about depression, but anxiety and depression so often travel together that these results add useful context.
As with any treatment still in clinical research, there are caveats. The Emerge results so far are topline findings announced by the company, not yet a full peer-reviewed publication, and only one of the two planned pivotal depression trials has reported.
The trial enrolled adults with major depression of meaningful severity (a MADRS score of at least 26), but it wasn’t designed specifically around treatment-resistant depression, so it can’t tell us how LSD would perform for people who’ve already been through multiple failed treatments.
As with every placebo-controlled psychedelic trial, there’s the issue of functional unblinding. When a drug changes your perception this dramatically, you can tell quickly whether you received it, and so can the clinicians rating your symptoms.
That’s why Ascend and the Panorama anxiety trial added a lower 50 µg dose as a comparison arm, an attempt to make it harder for participants to be certain which group they’re in.
None of this takes away from the promising results. For now, this is good news worth following closely.

What About Microdosing?
Microdosing refers to taking tiny, sub-perceptual amounts of LSD, which is different from the single full dose used in the trials above. The controlled evidence so far has been unimpressive.
A large self-blinding study of 191 participants found that people improved on microdoses, but improved just as much on placebo. A randomized trial in people with MDD at the University of Auckland, reported so far as a conference abstract, found microdosed LSD was not better than a caffeine placebo at reducing depression scores.
Early research, in other words, doesn’t support microdosing as a treatment for depression, even though anecdotal reports are enthusiastic.
Is LSD Therapy Safe? What We Know and What We Don’t
In Emerge, the vast majority of side effects were mild to moderate, passed within the dosing day, and were largely the perceptual effects you’d expect from the drug. Reportedly, there were no serious adverse effects or suicidality signals. That’s encouraging.
It’s also an early picture. This is a single-dose study in a small number of people over months, which says little about long-term outcomes, repeated use, or rarer effects that only appear across thousands of patients.
As with other psychedelics, people with a personal or family history of psychosis are typically excluded from trials, and interactions with other medications, particularly serotonin-based antidepressants, are still being worked out. In the company’s Phase 3 anxiety trials, participants received no add-on psychotherapy, anxiolytics, or antidepressants during the main study period, which is far more controlled than how depression is usually treated in real life.
Where Things Stand Legally
LSD remains a Schedule I controlled substance in the United States, which means the only legal way to receive it today is through a clinical trial. The regulatory picture is moving, though:
- Breakthrough Therapy designation: The FDA has granted DT120 this status twice, for anxiety in 2024 and for major depressive disorder in September 2026, a designation meant to speed up development of drugs that may offer a substantial improvement over existing treatments.
- Filing plans: The company expects a pre-NDA meeting with the FDA in the final quarter of 2026 and plans to file for anxiety in the first half of 2027. It hasn’t disclosed a submission timeline for depression.
- Still ahead: Even with FDA approval, LSD would need to be rescheduled by the DEA before it could be prescribed.
Realistically speaking, LSD therapy for major depressive disorder is not something you could access in the next year, and its timeline depends on a second trial, regulatory review, and rescheduling.
Psychedelic Therapies You Can Access Now
There’s a gap between “showing promise in clinical trials” and being available for patients, and right now, LSD therapy isn’t available.
At Kadelyx, we’re following these trials and how things develop, and we plan to introduce LSD therapy as soon as it’s cleared by the FDA, but in the meantime, other psychedelic-assisted therapy options are available.
Ketamine and esketamine (Spravato) both work through the brain’s glutamate system instead of serotonin, offering a different route than standard antidepressants, and both are legal, established, and in active clinical use.
Ketamine, given intravenously or sublingually, is used off-label for depression and has been studied for it for more than two decades.
Esketamine is a nasal spray, FDA-approved for treatment-resistant depression and for depression with suicidal thoughts, given in a certified clinic under observation.
Kadelyx offers both, and the right fit depends on your treatment history, your insurance, and what feels more comfortable to you.
Not Sure Where to Start? Talk to Us
Reading about treatments that aren’t available yet can leave you wondering what to do about the depression you have today. That’s a fair thing to bring to the Kadelyx team. We’ll go through what you’ve already tried, answer your questions plainly, and map out what ketamine-assisted treatment or Spravato could look like for you. A free consultation is just a conversation, and you can book one whenever you’re ready.





